Effect of Etoricoxib to Treat Chronic Low Back Pain (0663-041)

Phase 3CompletedNCT00393354

Organon and Co325 enrolled

Overview

Study the effect of etoricoxib 60 mg and 90 mg compared to placebo to treat chronic low back pain.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

325

Conditions

Recurrent Low Back Pain

Interventions

MK0663, Etoricoxib / Duration of Treatment : 12 WeeksDRUG

Comparator : placebo (unspecified) /Duration of Treatment : 12 WeeksDRUG

Eligibility

Sex: ALLMin age: 18 YearsMax age: 75 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Low back pain for previous 3 months and majority of days in last month * Regular use of acetaminophen or NSAID to treat low back pain in past month * Judged to be in otherwise good health Exclusion Criteria: * Low back pain that is due to secondary causes * Radicular/myelopathic pain * Surgery for low back pain within the past 6 months * Active lawsuit or claim pertaining to their low back pain * Disease that may confound the results of the study or pose risk to the patients * Corticosteroid use in past month * Previous participation in MK0663 study

Outcomes

Primary Outcomes

Low back pain intensity scale (0-100 mm VAS) over 4 weeks compared to placebo

Secondary Outcomes

Low back pain intensity scale (0-100 mm VAS) over 12 weeks compared to placebo

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.